NCT00358930View on ClinicalTrials.gov

A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck

PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

August 31, 2007

Study Completion Date

August 31, 2007

Conditions
Head and Neck NeoplasmsCarcinoma, Squamous Cell
Interventions
DRUG

ARQ 501

Trial Locations (9)

12208

New York Oncology Hematology, Albany

36693

University of South Alabama, Mobile

60637

University of Chicago Medical Center, Chicago

63110

Washington University School of Medicine, St Louis

75201

Mary Crowley Medical Research Center, Dallas

90033

LA County Hospital, Los Angeles

90089-0178

Norris Comprehensive Cancer Center, Los Angeles

02115

Dana-Farber Cancer Institute, Boston

02218

Dana-Farber, Boston

All Listed Sponsors
lead

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

INDUSTRY

NCT00358930 - A Study of ARQ 501 in Patients With Squamous Cell Carcinoma of the Head and Neck | Biotech Hunter | Biotech Hunter